The FDA has approved a generic version of the GLP-1 RA liraglutide for people with type 2 diabetes to lower blood sugar. This follows the approval of a generic version of exenatide last month to improve access to GLP-1 medications due to shortages. The FDA supports the development of generic drugs, including GLP-1s, to increase patient access to affordable treatment options. Common side effects of liraglutide injection include nausea, diarrhea, and vomiting. The approval is part of the FDA’s Drug Competition Action Plan to promote generic competition and increase access to complex drug products like liraglutide. Hikma Pharmaceuticals USA Inc. received the approval for generic liraglutide injection.
Source link
FDA Approves Second Generic Daily GLP-1 Drug for T2D
